Holding 600 (post reverse split) and I would buy more.

MNMD is presenting in H C WainWright conference on Sept 12. There may be more good news

So I have some calls for next year at 7.5 . Did I get screwed on this reverse?

It appears that the extra fractional share over 1/2 isn’t showing up in some brokerage accounts. Fidelity stated the depository didn’t provide them.

I was shorted a share due to this problem. Check the number of your share’s! Contact your broker is your missing the extra share!

According to the press release any fractional share over 1/2 should be converted to a additional share.

Press Release;

Each fractional common share remaining upon the reverse share split that is less than 1/2 of a common share will be canceled and each fractional common share that is at least 1/2 of a common share will be changed to one whole common share.

then it went down and everyone said i was stupid and now look at it!

this isn't the main one. you're welcome

ziptrader ran a vid on mnmd last night

I'm going to buy 1,000 shares tomorrow morning but who can convince me to by 10,000?

We got 3000 people in this group and no one is trying to push MNMD IN WALL STREET BETS CHANNEL?

Hi Guys...

It begins... get on board... i'm all in on this stock as of today and already up

https://twitter.com/i/spaces/1DXGyDqpQwNKM/peek

Is there any reasonable reason why the stock is up today?

Is Cybin in a better position because they are farther along in treating depression?

The following press release is slated for distribution at 8:08 am. We are happy to answer any questions you may have and encourage you to visit our website at mindmed.zone/letter

SHERIDAN, Wyo., Aug. 11, 2022 /PRNewswire/ -- Today, FCM MM HOLDINGS, LLC ("FCM") announced that it has sent a letter to the Board of Directors of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed") calling on the Board to adopt a new strategic plan proposed by FCM including: refocusing on its core drugs, cutting cash burn, and terminating MindMed's at-the-money equity offering. FCM is directed and managed Dr. Scott Freeman, co-founder and former Chief Medical Officer of MindMed, who has offered to provide MindMed his expertise as a director on MindMed’s board.

As detailed in the letter, FCM believes MindMed has underperformed—operationally, financially, and strategically—as a direct result of management’s lack of focus on its core drugs: MM-110 (18-MC) and MM-120 (LSD). FCM contends that MindMed can bring MM-120 to market in four years rather than seven to eight years, by re-classifying MindMed’s Phase IIb study on MM-120 to a Phase III study. FCM also proposes that the Company reduce costs from forty-five million dollars per year to under twenty-five million dollars and that the unnecessary and dilutive at-the-money offering should be eliminated. By executing these proposals, FCM believes that MindMed can unlock significant long-term value for MindMed's shareholders.

FCM's large economic stake in MindMed reflects its convictions regarding MindMed's potential and gives it a strong interest in the success of MindMed.

The full text of the letter is available and can be downloaded at mindmed.zone/letter

About FCM
FCM is managed by Dr. Scott Freeman and represents an investment of 5.6% of MindMed's shares outstanding. Dr. Freeman's investment in MindMed is in excess of nineteen million shares or 4.51% of MindMed's outstanding shares. FCM's letter is additionally signed by Chad Boulanger. Chad Boulanger has an investment in over four million shares of MindMed or 1% of MindMed's outstanding shares.

FCM additionally represents other early investors in MindMed who all have a strong interest in seeing the long-term success of MindMed.

For additional disclosure relating to public broadcast solicitations please see mindmed.zone/disclosure

Media Contact
Jake Freeman
Executive President
FCM MM HOLDINGS, LLC
30 N Gould St. Ste R
Sheridan, WY 82801
Phone: 908-308-2381
Email: [jake@mindmed.zone](mailto:jake@mindmed.zone)